Myelom-Gruppe Rhein-Main

Last modified: 12 January 2013

High dosage therapy and stem cell transplantation

Studies have shown that the use of melphalan in very high dosages has led to full remission (complete disappearance of the symptoms of the illness) with many patients. Nevertheless, the high dosage therapy had a negative effect on the bone marrow. The result is a pronounced lack of white blood cells, combined with a major risk of infection. The following procedures have now become established for high-dosage multiple myeloma therapy:

  • Administering of growth factors that accelerate the regeneration of white blood cells. These growth factors are known as granulocyte colony-stimulating factors (G-CSF).
  • Re-transplanting of bone marrow - or of periphery stem cells (circulating in the blood) obtained prior to the high dosage therapy. This procedure is also referred to as autologous (obtained from the own body) stem cell transplantation.

Consult your doctor as to whether this form of autologous or even allogenic (stem cells from another person) transplantation, in combination with high-dosage chemotherapy, can be considered in your case and regarding the risks associated with these methods.